We are delighted to announce that our team will have a booth at the #ESGCT 2024 which is taking place in Rome, Italy, from 22nd-25th October 🏛️ The conference marks an unmissable date in the calendar with invaluable industry insights. If you are planning on attending, please make sure you find our team Dr Daria Olijnyk-Dallis Nolan Talhi Lisa Caproni, PhD and Tom Merritt at our booth A18! 🤝 #Touchlight #ESGCT24 #CellTherapy #dbDNA
Touchlight
Biotechnology Research
Hampton, London, England 18,819 followers
The Making of DNA
About us
Touchlight is an innovation-driven leading CDMO pioneering enzymatic DNA production to enable the genetic medicine revolution. As pioneers with an FDA Drug Master Filing already accepted in 2022, our enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and in vivo gene editing innovation. With multiple client products already in the clinic, our evidence-based, data-supported synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. Our company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, our team is inspired by breakthroughs in genome sequencing, recognizing the urgent need for innovative DNA production techniques to support the future of genetic therapies. To address these challenges, we developed our first novel synthetic DNA vector, dbDNA™, alongside a proprietary enzymatic manufacturing process. This groundbreaking approach enables the production of complex DNA sequences with remarkable speed, scale, and purity, surpassing the limitations of traditional pDNA production while transforming the economics of bringing these therapies to market more efficiently and sustainably. Touchlight’s commitment to innovation is continually fueling product improvements and new product development. As of early 2024, we have partnered with hundreds of biotech and top 10 pharmaceutical companies, producing synthetic DNA for use as both a starting material and an active pharmaceutical ingredient. By the end of this year, dbDNA™ will be one of multiple synthetic DNA products in our portfolio that will continue to pave the way for more accessible cell and gene therapies.
- Website
-
http://www.touchlight.com
External link for Touchlight
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Hampton, London, England
- Type
- Privately Held
- Founded
- 2008
- Specialties
- Genetic Medicine, DNA therapeutics, DNA vaccines, Enzymatic technology, Contract manufacturing, Oncology, AAV, mRNA, CDMO, synthetic DNA, Lentivirus, Gene therapy, DNA, Genome editing, Biotechnology, Life Science, Plasmids, Advanced Therapies, Pharma, and Cell Therapy
Locations
-
Primary
Hampton, London, England TW12 2ER, GB
-
Morelands & Riverdale Buildings,
Lower Sunbury Road,
Hampton, England TW12 2ER, GB
-
Morelands & Riverdale Buildings,
Lower Sunbury Road,
Hampton, TW12 2ER, GB
Employees at Touchlight
Updates
-
What is dbDNA™? Named after its schematic structure, dbDNA™ is a minimal, linear, double stranded and covalently closed DNA construct that can encode long, complex, or unstable DNA sequences, eliminates bacterial sequences and has a strong expression profile. Learn how Touchlight is making DNA simple by moving away from restrictive biological approaches and instead using enzyme biochemistry, eliminating the need for bacterial sequences: #biotech #drugdevelopment #biopharma #pharma
-
Touchlight to supply GMP dbDNA to support University of Nottingham’s clinical study for a next-generation vaccine for Zika virus. This innovative project is funded by the Department of Health and Social Care (DHSC) as part of the UK Vaccine Network, a UK aid programme dedicated to developing vaccines for diseases with epidemic potential in low and middle-income countries. Read the full press release here: https://lnkd.in/epAy9VmA #GMP #pharma #innovation #biotech
-
With Meeting on the Mesa only next week, Verna Mc Erlane and Dr Daria Olijnyk-Dallis are gearing up for an unforgettable experience in Phoenix, AZ. Make sure you find and connect with us if you are going! 🤝 #Touchlight #CGMesa24 #dbDNA
Touchlight are excited to be heading to this year's Cell and Gene Meeting on the Mesa 2024 which is taking place in Phoenix, Arizona! 🌵 Please come and connect with our SVP Global Head of Sales, Verna Mc Erlane and our European Sales Director, Dr Daria Olijnyk-Dallis who are looking forward to discussing our synthetic DNA (dbDNA) in your cell and cell & gene therapy applications 🤝 👉 https://lnkd.in/g2-Pe8P #Touchlight #CGMesa24 #dnDNA
-
dbDNA™ is substitutable for plasmid DNA in AAV (adeno-associated virus) production by transient transfection, typically requiring less DNA material for equivalent infectious titres, and eliminating packaging of bacterial sequences. Replacing plasmid DNA with enzymatically produced dbDNA™ in your AAV production eliminates many issues around complex or unstable sequences, alongside improved speed to manufacture, safety and scalability. Find out more about DNA supply for AAV production: https://lnkd.in/ePgVEjgW #genetherapy #pharma #biotech #AAV
-
DNA development and manufacturing to support your advanced therapy production. Touchlight offers a range of services including contract development and manufacturing to support development and commercialisation of the next generation of DNA products. Find out more about our contract development and manufacturing capabilities: https://lnkd.in/ePYGCq4V #genetherapy #pharma #biotech #dbDNA
-
Touchlight’s MegaBulb DNA is addressing critical challenges in CRISPR technology. Our latest article delves into how this synthetic ssDNA solution is transforming the field by providing: + Enhanced editing efficiency + Reduced cellular toxicity + Easily scalable production Want to stay ahead in the rapidly evolving world of gene therapy? Read the article from our own Elena Stoyanova, PhD and Tom Adie, PhD: https://lnkd.in/euxV8vmk #genetherapy #pharma #advancedtherapies #biotech
-
The genetic medicines market has grown dramatically in recent years, with advanced therapies driving transformational improvements in the treatment of devastating diseases. dbDNA™ is an alternative to plasmid DNA in lentivirus production by transient transfection, requiring less DNA material for at least equivalent infectious titres. Gain insight on our work and research into lentiviruses: https://lnkd.in/eZCXupgN #genetherapy #pharma #biotech #lentivirus
-
Touchlight are excited to be heading to this year's Cell and Gene Meeting on the Mesa 2024 which is taking place in Phoenix, Arizona! 🌵 Please come and connect with our SVP Global Head of Sales, Verna Mc Erlane and our European Sales Director, Dr Daria Olijnyk-Dallis who are looking forward to discussing our synthetic DNA (dbDNA) in your cell and cell & gene therapy applications 🤝 👉 https://lnkd.in/g2-Pe8P #Touchlight #CGMesa24 #dnDNA
-
Are you working on developing new gene therapies? Touchlight's innovative MegaBulb DNA might be the solution you've been looking for. This non-viral ssDNA template is setting new standards in CRISPR applications. A recent article by Touchlight’s Senior Scientist Elena Stoyanova, PhD and Associate Director of Research Tom Adie, PhD explores how MegaBulb DNA outperforms traditional HDR templates’ genome repair rates, offering more consistent results. Discover the potential of MegaBulb DNA for your research. Check out our latest publication and join the gene editing revolution: https://lnkd.in/euxV8vmk #genetherapy #pharma #lifesciences #DNA